Skip to Content

Clopidogrel Sandoz

Active Substance: clopidogrel
Common Name: clopidogrel
ATC Code: B01AC04
Marketing Authorisation Holder: Acino Pharma GmbH
Active Substance: clopidogrel
Status: Withdrawn
Authorisation Date: 2009-09-21
Therapeutic Area: Peripheral Vascular Diseases Stroke Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
* Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
For further information please refer to section 5.1.

The marketing authorisation for Clopidogrel Sandoz has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide